Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children,
with survival rates lagging well behind those observed at initial diagnosis. Although there …

Since the identification of B‐cell translocation gene 1 (BTG1) and BTG2 as antiproliferation
genes more than two decades ago, their protein products have been implicated in a variety …

Importance Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with
efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) …

Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions of
relapsed/refractory B-acute lymphoblastic leukemia (ALL). However, case reports suggested …

Purpose Minimal residual disease (MRD) and genetic abnormalities are important risk
factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize …

Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly
penetrant cancer predisposition condition. Recent reports of germline TP53 variants in …

PURPOSE The International Berlin-Frankfurt-Münster (BFM) study group conducted a study
on pediatric acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) was …

Improved personalized adjustment of primary therapy to the perceived risk of relapse by
using new prognostic markers for treatment stratification may be beneficial to patients with …

Simple Summary Acute lymphoblastic leukemia is the most common blood cancer in
pediatric patients. Despite the enormous progress in ALL treatment, which is reflected by a …

Hyperdiploidy is the largest genetic entity B-cell precursor acute lymphoblastic leukemia in
children. The diagnostic hallmark of its two variants that will be discussed in detail herein is …